Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma has unveiled an $80M investment plan to expand its Lexington, Kentucky facility.
The site specializes in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products, playing a vital role in Piramal Pharma Solutions integrated antibody‐drug conjugate development and manufacturing program, ADCelerate. The investment, financed by bank loans and internal accruals, aims to enhance the site's existing capacity and capabilities to meet the demands of a rapidly growing market.
With this expansion, Piramal Pharma will strengthen its position as an efficient and reliable global partner for biologic manufacturing, leveraging deep scientific expertise and extensive experience managing complex technical projects.
The expansion will equip the Lexington site with an additional 24,000 square feet of manufacturing space, a new laboratory, and state‐of‐the‐art machinery to scale clients' products effectively. Key additions include a new filling line, two commercial‐size lyophilizers, a special capping machine, and an external vial washer.
Currently, the Lexington site can manufacture 104 product batches per year (utilization at peak levels). Upon completion of the expansion in Q1 of 2027, this capacity will increase to over 240 annual batches.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
